LXH254

Research use only, not for human use.

LXH254 (LXH-254, LXH 254) is a novel potent, ATP-competitive pan-RAF inhibitor, binds to Raf proteins and inhibits Raf-mediated signal transduction pathways.

LXH254 (LXH-254, LXH 254) is a novel potent, ATP-competitive pan-RAF inhibitor, binds to Raf proteins and inhibits Raf-mediated signal transduction pathways, inhibits proliferation of Raf-overexpressing tumor cells; demonstrates anti-proliferative activity in cell lines that contain a variety of mutations that activate MAPK signaling, blocks mutant RAS-driven signaling and cell proliferation; demonstrates tumor regression in several KRAS-mutant models including the NSCLC-derived Calu-6 (KRAS Q61K) and NCI-H358 (KRAS G12C), exhibits efficacy in numerous MAPK-driven human cancer cell lines and in xenograft tumors representing model tumors harboring human lesions in KRAS, NRAS and BRAF oncogenes.Lung Cancer Phase 1 Clinical(In Vitro):LXH254 (Compound A) is an adenosine triphosphate (ATP)-competitive inhibitor of BRAF (also referred to herein as b-RAF or b-Raf) and CRAF (also referred to herein as c-RAF or c- Raf) protein kinases. Throughout the present disclosure, LXH254 is also referred to as a c-RAF (or CRAF) inhibitor or a C-RAF/c-Raf kinase inhibitor. In cell-based assays, LXH254 has demonstrated anti-proliferative activity in cell lines that contain a variety of mutations that activate MAPK signaling. Moreover, LXH254 is a Type 2 ATP -competitive inhibitor of both B-Raf and C-Raf that keeps the kinase pocket in an inactive conformation, thereby reducing the paradoxical activation seen with many B-Raf inhibitors, and blocking mutant RAS-driven signaling and cell proliferation.LXH254 (0-10 μM, 1 h) inhibits both monomeric and dimeric RAF and promotes RAF dimer formation.LXH254 has reduced ability to suppress MAPK signaling driven by ARAF and further that the contribution of ARAF to MAPK signaling increases in the absence of CRAF expression.LXH254 shows more sensitivity when cells lack ARAF.(In Vivo):Treatment with LXH254 (Compound A) generates tumor regression in several KRAS-mutant models including the NSCLC-derived Calu-6 (KRAS Q61K) and NCI-H358 (KRAS G12C). LXH254 exhibits efficacy in numerous MAPK-driven human cancer cell lines and in xenograft tumors representing model tumors harboring human lesions in KRAS, NRAS and BRAF oncogenes.LXH254 shows significant antitumor activity in models harboring BRAF mutations either alone or coincident with either activated NRAS or KRAS, and RAS mutants lacking ARAF are more sensitive to LXH254.

LXH254 (Compound A) is an adenosine triphosphate (ATP)-competitive inhibitor of BRAF (also referred to herein as b-RAF or b-Raf) and CRAF (also referred to herein as c-RAF or c- Raf) protein kinases. Throughout the present disclosure, LXH254 is also referred to as a c-RAF (or CRAF) inhibitor or a C-RAF/c-Raf kinase inhibitor. In cell-based assays, LXH254 has demonstrated anti-proliferative activity in cell lines that contain a variety of mutations that activate MAPK signaling. Moreover, LXH254 is a Type 2 ATP -competitive inhibitor of both B-Raf and C-Raf that keeps the kinase pocket in an inactive conformation, thereby reducing the paradoxical activation seen with many B-Raf inhibitors, and blocking mutant RAS-driven signaling and cell proliferation.LXH254 (0-10 μM, 1 h) inhibits both monomeric and dimeric RAF and promotes RAF dimer formation.LXH254 has reduced ability to suppress MAPK signaling driven by ARAF and further that the contribution of ARAF to MAPK signaling increases in the absence of CRAF expression.LXH254 shows more sensitivity when cells lack ARAF.Western Blot Analysis Cell Line:HCT116, MEL-JUSO, Mia PaCa-2, A375(BRAFV600E), and HCT116 (KRASG13D)Concentration:0-10 μM Incubation Time:1 hResult:Promoted B/CRAF heterodimer formation. Displayed similar inhibition of monomeric BRAFV600 and wild-type dimeric RAF (IC50 for p-ERK levels of 59 and 78 nmol/L in A-375 and HCT 116 cells, respectively).Cell Proliferation Assay Cell Line:Two NRAS-mutant melanoma cell lines (MEL-JUSO and SK-MEL-30), three KRAS-mutant cell lines (COR-L23, MIA PaCa-2, and HCT116), and derived variants lacking expression of either ARAF, BRAF, or CRAF.Concentration:0-10 μM Incubation Time:24 h Result:The sensitivity was increased relative to parental cell lines in all models tested by loss of ARAF expression.

Treatment with LXH254 (Compound A) generates tumor regression in several KRAS-mutant models including the NSCLC-derived Calu-6 (KRAS Q61K) and NCI-H358 (KRAS G12C). LXH254 exhibits efficacy in numerous MAPK-driven human cancer cell lines and in xenograft tumors representing model tumors harboring human lesions in KRAS, NRAS and BRAF oncogenes.LXH254 shows significant antitumor activity in models harboring BRAF mutations either alone or coincident with either activated NRAS or KRAS, and RAS mutants lacking ARAF are more sensitive to LXH254. Animal Model:Outbred athymic (nu/nu) female mice and SCID Beige mice; BRAF-, NRAS-, and KRAS-mutant xenograft models, as well as a RAS/RAF wild-type model Dosage:100 mg/kg Administration:Orally, daily Result:Significantly decreased tumor volume in models harboring BRAF mutations either alone or coincident with either activated NRAS or KRAS, slightly decreased tumor volume in KRAS model.

LXH-254 | LXH 254

MAPK/ERK Signaling

Raf

Raf

Cancer

Lung Cancer

1800398-38-2

502.494

C25H25F3N4O4

>98% (HPLC)

DMSO : ≥ 83.3 mg/mL 165.77 mM

CC1=C(C=C(C=C1)NC(=O)C2=CC(=NC=C2)C(F)(F)F)C3=CC(=NC(=C3)OCCO)N4CCOCC4

N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

(-20℃)

With Ice Pack

≥ 2 years